Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Karami F, Mehdipour P.

Biomed Res Int. 2013;2013:928562. doi: 10.1155/2013/928562. Epub 2013 Nov 7. Review.

2.

Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.

Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES.

PLoS One. 2012;7(9):e43994. doi: 10.1371/journal.pone.0043994. Epub 2012 Sep 7.

3.

Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation.

Seong MW, Cho S, Noh DY, Han W, Kim SW, Park CM, Park HW, Kim SY, Kim JY, Park SS.

Clin Genet. 2009 Aug;76(2):152-60. doi: 10.1111/j.1399-0004.2009.01202.x. Epub 2009 Jul 28.

PMID:
19656164
4.

BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.

Perkowska M, BroZek I, Wysocka B, Haraldsson K, Sandberg T, Johansson U, Sellberg G, Borg A, Limon J.

Hum Mutat. 2003 May;21(5):553-4.

PMID:
12673801
5.

Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.

Kim YC, Zhao L, Zhang H, Huang Y, Cui J, Xiao F, Downs B, Wang SM.

Oncotarget. 2016 Feb 23;7(8):9600-12. doi: 10.18632/oncotarget.7144.

6.

Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.

Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.

Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18.

7.
9.

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.

Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M.

Breast Cancer Res Treat. 2011 Aug;129(1):185-90. doi: 10.1007/s10549-011-1433-2. Epub 2011 Mar 11.

10.

BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.

Cecener G, Egeli U, Tunca B, Erturk E, Ak S, Gokgoz S, Tasdelen I, Tezcan G, Demirdogen E, Bayram N, Avci N, Evrensel T.

Cancer Invest. 2014 Oct;32(8):375-87. doi: 10.3109/07357907.2014.919302. Epub 2014 Jun 2.

PMID:
24884828
11.

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.

PMID:
15564800
12.

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.

Am J Hum Genet. 1997 Mar;60(3):505-14.

13.

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.

Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V.

Neoplasma. 2006;53(2):97-102.

PMID:
16575464
14.

[Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].

Nasedkina TV, Gromyko OE, Emel'ianova MA, Ignatova EO, Kazubskaia TP, Portnoĭ SM, Zasedatelev AS, Liubchenko LN.

Mol Biol (Mosk). 2014 Mar-Apr;48(2):243-50. Russian.

15.

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D.

Am J Hum Genet. 1997 May;60(5):1059-67.

16.

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.

Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.

17.

Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.

Stadler ZK, Saloustros E, Hansen NA, Schluger AE, Kauff ND, Offit K, Robson ME.

Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11.

PMID:
20221693
18.

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.

Cao WM, Gao Y, Yang HJ, Xie SN, Ding XW, Pan ZW, Ye WW, Wang XJ.

BMC Cancer. 2016 Feb 6;16:64. doi: 10.1186/s12885-016-2107-6.

19.

Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.

Burcoş T, Cimponeriu D, Ion DA, Spandole S, Apostol P, Toma M, Radu I, Popa I, Stanilescu S, Popa E.

Chirurgia (Bucur). 2013 Jul-Aug;108(4):468-72.

20.

Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.

Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, Hocevar M, De Grève J.

BMC Med Genet. 2008 Sep 10;9:83. doi: 10.1186/1471-2350-9-83.

Supplemental Content

Support Center